<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00233545</url>
  </required_header>
  <id_info>
    <org_study_id>01-2005</org_study_id>
    <nct_id>NCT00233545</nct_id>
  </id_info>
  <brief_title>Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia</brief_title>
  <official_title>Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Foundation</source>
  <brief_summary>
    <textblock>
      Cutaneous leishmaniasis is typically treated with the parenteral product pentavalent
      antimony. Miltefosine is an oral agent shown to be active for mucosal leishmaniasis due to L
      braziliensis in Bolivia and cutaneous leishmaniasis due to L panamensis in Colombia. This
      trial is intended to evaluate miltefosine for cutaneous leishmaniasis due to L braziliensis
      in Bolivia. Patients will be randomly assigned to miltefosine or pentavalent antimony.
      Standard dose regimens will be used for both drugs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date>September 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cure rate</measure>
  </primary_outcome>
  <enrollment>80</enrollment>
  <condition>Cutaneous Leishmaniasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>miltefosine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antimony</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Presentation: At least 1 lesion must be ulcerative. Parasitology: Parasitological
        confirmation of 1 lesion will be made by visualization or culture of leishmania from the
        biopsy or aspirate of the lesion.

        Previous RX: No specific or putatively specific therapy for leishmaniasis (Sb, pentamidine,
        amphotericin B, imidazoles, allopurinol)

        Other diseases: No concomitant diseases by history and by approximately normal complete
        blood counts (white blood count, hemoglobin, platelet count), values of liver transaminases
        (SGOT) and kidney function tests (creatinine).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Soto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FADER</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Puesto de Salud, Campamento OSCAR,</name>
      <address>
        <city>Palos Blancos,</city>
        <country>Bolivia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bolivia</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2005</study_first_submitted>
  <study_first_submitted_qc>October 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2005</study_first_posted>
  <last_update_submitted>May 29, 2010</last_update_submitted>
  <last_update_submitted_qc>May 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2010</last_update_posted>
  <keyword>cutaneous</keyword>
  <keyword>leishmaniasis</keyword>
  <keyword>drug</keyword>
  <keyword>miltefosine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miltefosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

